Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naim Alkhouri

Showing results (221-230 of 306) with videos related to

Pageof 31
Sort By:
Journal of Hepatology|September 26, 2024
Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASHNaim Alkhouri, Cayden Beyer, Elizabeth Shumbayawonda, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 6, 2022
Disease State Transition Probabilities Across the Spectrum of NAFLD: A Systematic Review and Meta-Analysis of Paired Biopsy or Imaging StudiesPhuc Le, Julia Yang Payne, Lu Zhang, et al.
Alimentary Pharmacology & Therapeutics|April 6, 2026
Review Article: An Update on Non-Invasive Tests for Steatotic Liver Disease - Insights From the ESSENCE Phase 3 Trial and Longitudinal StudiesNaim Alkhouri, Naga Chalasani, Zobair Younossi, et al.
Digestive Diseases and Sciences|June 15, 2021
Incidence of Complications from Percutaneous Biopsy in Chronic Liver Disease: A Systematic Review and Meta-AnalysisHelena B Thomaides-Brears, Naim Alkhouri, Daniela Allende, et al.
The Lancet. Gastroenterology & Hepatology|September 6, 2024
Best buy interventions to address the burden of steatotic liver diseaseJeffrey V Lazarus, Henry E Mark, Naim Alkhouri, et al.
Transplantation|September 16, 2016
Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center ExperienceMohamed A Elfeki, Rachel Abou Mrad, Jamak Modaresi Esfeh, et al.
The Lancet. Gastroenterology & Hepatology|June 12, 2026
Propelling MASLD trials into the era of non-invasive testsLi-You Lian, Wen-Yue Liu, Wenhao Li, et al.
The Lancet. Gastroenterology & Hepatology|August 3, 2025
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy studyVincent Wai-Sun Wong, Neeta B Amin, Hirokazu Takahashi, et al.
JAMA Network Open|January 17, 2025
Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050Phuc Le, Moosa Tatar, Srinivasan Dasarathy, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 31, 2024
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASHNaim Alkhouri, Carl LaCerte, Jeffrey Edwards, et al.
Pageof 31

Showing results (221-230 of 306) with videos related to

Sort By:
Pageof 31
Journal of Hepatology|September 26, 2024
Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASHNaim Alkhouri, Cayden Beyer, Elizabeth Shumbayawonda, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 6, 2022
Disease State Transition Probabilities Across the Spectrum of NAFLD: A Systematic Review and Meta-Analysis of Paired Biopsy or Imaging StudiesPhuc Le, Julia Yang Payne, Lu Zhang, et al.
Alimentary Pharmacology & Therapeutics|April 6, 2026
Review Article: An Update on Non-Invasive Tests for Steatotic Liver Disease - Insights From the ESSENCE Phase 3 Trial and Longitudinal StudiesNaim Alkhouri, Naga Chalasani, Zobair Younossi, et al.
Digestive Diseases and Sciences|June 15, 2021
Incidence of Complications from Percutaneous Biopsy in Chronic Liver Disease: A Systematic Review and Meta-AnalysisHelena B Thomaides-Brears, Naim Alkhouri, Daniela Allende, et al.
The Lancet. Gastroenterology & Hepatology|September 6, 2024
Best buy interventions to address the burden of steatotic liver diseaseJeffrey V Lazarus, Henry E Mark, Naim Alkhouri, et al.
Transplantation|September 16, 2016
Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center ExperienceMohamed A Elfeki, Rachel Abou Mrad, Jamak Modaresi Esfeh, et al.
The Lancet. Gastroenterology & Hepatology|June 12, 2026
Propelling MASLD trials into the era of non-invasive testsLi-You Lian, Wen-Yue Liu, Wenhao Li, et al.
The Lancet. Gastroenterology & Hepatology|August 3, 2025
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy studyVincent Wai-Sun Wong, Neeta B Amin, Hirokazu Takahashi, et al.
JAMA Network Open|January 17, 2025
Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050Phuc Le, Moosa Tatar, Srinivasan Dasarathy, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 31, 2024
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASHNaim Alkhouri, Carl LaCerte, Jeffrey Edwards, et al.
Pageof 31